SYMBIOSE - Descriptive pharmaco-epidemiological study on the use of Symbicort® Turbuhaler® in the treatment of asthma in France and impact of a new treatment strategy on compliance and asthma control

Head :Piedbois Pascal
Thomas-Delecourt Florence, AstraZeneca

Last update : 12/13/2013 | Version : 4 | ID : 188

General

Identification

Detailed name	Descriptive pharmaco-epidemiological study on the use of Symbicort® Turbuhaler® in the treatment of asthma in France and impact of a new treatment strategy on compliance and asthma control
Sign or acronym	SYMBIOSE
CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation	CNIL : 908418 - 28/01/2009

General Aspects

Medical area	General practice Pneumology
Keywords	Symbicort® Turbuhaler®, cohort

Scientific investigator(s) (Contact)

Name of the director	Piedbois
Surname	Pascal
Address	3, rue de la Porte de l'hôpital 67065 Strasbourg Cedex, France
Phone	+33-388252401
Email	ppiedbois@strasbourg.unicancer.fr
Organization	Centre Paul Strauss
Name of the director	Thomas-Delecourt

Surname	Florence
Phone	+33 (0)1 41 29 40 25
Email	florence.thomas@astrazenzca.com
Unit	AstraZeneca

Collaborations

Funding

Funding status	Private
Details	AstraZeneca

Governance of the database

Sponsor(s) or organisation(s) responsible	ASTRAZENECA
Organisation status	Private

Additional contact

Main features

Type of database

Type of database	Study databases
Study databases (details)	Longitudinal study (except cohorts)
Database recruitment is carried out by an intermediary	A selection of health institutions and services
Database recruitment is is made on the basis of:	Medication(s) taken
Database recruitment is carried out as part of an interventional study	No
Additional information regarding sample selection.	The physicians and the pulmonologists participating in the study recruit the subjects to be included among the patients that they see in consultation and according to the inclusion criteria

Database objective

Main objective	Describe the characteristics of asthmatic patients treated with Symbicort Turbuhaler

	Compare the characteristics of patients treated according to the therapeutic strategy Evaluate the level of asthma control and compliance with treatment of patients treated with Symbicort Turbuhaler
Inclusion criteria	Patients diagnosed as asthmatic by the physician and treated for this pathology with Symbicort Turbuhaler
Population type	
Age	Childhood (6 to 13 years) Adolescence (13 to 18 years) Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years) Great age (80 years and more)
Population covered	Sick population
Gender	Male Woman
Geography area	National
Detail of the geography area	France
Data collection	
Dates	
Date of first collection (YYYY or MM/YYYY)	2009
Date of last collection (YYYY or MM/YYYY)	2011
Size of the database	
Size of the database (number of individuals)	[1000-10 000[individuals
Details of the number of individuals	1844
Data	
Database activity	Current data collection
Type of data collected	Clinical data Declarative data

Clinical data (detail)	Medical registration
Declarative data (detail)	Phone interview
Presence of a biobank	No
Health parameters studied	Health event/morbidity Quality of life/health perception
Procedures	
Participant monitoring	Yes
Details on monitoring of participants	Follow-up duration of 12 months
Links to administrative sources	No
Promotion and access	
Promotion	
Access	
Terms of data access (charter for data provision, format of data, availability delay)	Methods for accessing the database are currently being defined
Access to aggregated data	Access on specific project only
Access to individual data	Access on specific project only